Sierra Mei Lin Centkowski, MD
Dermatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Centkowski’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A165376 · Current
Licensed to practise in California · since 2019 · expires 2027-09-30 · Perelman School of Medicine at the University of Pennsylvania.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$66,316
Medicare paid this office $66,316 for 315 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 193 | $22,282 | $79 |
| Return visit (30+ min) | 58 | $8,270 | $115 |
| New patient visit (30+ min) | 83 | $7,069 | $85 |
| Destruction of precancer skin growth, 1 growth | 100 | $7,003 | $52 |
| Destruction of skin growth, 1-14 growths | 45 | $6,881 | $103 |
See all 9 services
| Short return visit (20+ min) | 193 | $22,282 | $79 |
| Return visit (30+ min) | 58 | $8,270 | $115 |
| New patient visit (30+ min) | 83 | $7,069 | $85 |
| Destruction of precancer skin growth, 1 growth | 100 | $7,003 | $52 |
| Destruction of skin growth, 1-14 growths | 45 | $6,881 | $103 |
| Biopsy of related skin growth, first growth | 58 | $5,921 | $90 |
| New patient visit (45+ min) | 19 | $2,849 | $150 |
| Destruction of precancer skin growth, 2-14 growths | 69 | $1,740 | $7 |
| Biopsy of related skin growth, each additional growth | 11 | $568 | $52 |
Procedures Medicare counted
| Removal of skin lesions | 309 | More than 82% of doctors who do this |
| Skin biopsy | 77 | More than 73% of doctors who do this |
Who their Medicare patients are
315 Original Medicare patients in 2024. Average age 74 · Under 65 8% · 85 and older 15% · Women 53% · Also on Medicaid 14% · Health risk score 1.11. Above the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 56% · Coronary heart disease 22% · Cancer 20% · Diabetes 19% · Chronic kidney disease 17% · Depression 17% · Atrial fibrillation 14% · Heart failure 9% · COPD 8% · Dementia 8% · Stroke 6%.
The office billed $308,019, Medicare allowed $92,344 and paid $66,316; for 1,160 services of 23 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 315 | 1,160 | 74 | 1.11 | $308,019 | $66,316 |
| 2023 | 214 | 708 | 73 | 1.24 | $419,706 | $50,087 |
| 2022 | 42 | 99 | 72 | 1.00 | $80,652 | $7,507 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Short return visit (20+ min) | 117 | $13,268 | $80 |
| Return visit (30+ min) | 35 | $6,601 | $114 |
| Destruction of skin growth, 1-14 growths | 45 | $5,660 | $111 |
| New patient visit (30+ min) | 55 | $5,435 | $99 |
| New patient visit (45+ min) | 33 | $4,586 | $139 |
| Destruction of precancer skin growth, 1 growth | 61 | $3,761 | $49 |
| Biopsy of related skin growth, first growth | 29 | $2,793 | $93 |
| Punch biopsy, first skin growth | 16 | $1,949 | $122 |
| Destruction of precancer skin growth, 2-14 growths | 41 | $828 | $6 |
| Telehealth originating site facility fee | 26 | $808 | $22 |
2022: 3 services
| Return visit (30+ min) | 15 | $1,791 | $105 |
| Short return visit (20+ min) | 12 | $1,259 | $84 |
| Destruction of precancer skin growth, 1 growth | 11 | $546 | $45 |
Medicaid work
$8,464 in 2024
Medicaid paid $8,464 for 113 billed services this clinician did in 2024, up to 22 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 85 | $5,480 |
| Return visit (30+ min) | 28 | $2,984 |
| 2024 | 113 | 2 | 22 | $8,464 |
Drugs they prescribed that Part D paid
$400,105
Pharmacies billed $400,105 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 597) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
523 generic and 74 brand-name prescriptions · $400,105 in drug cost · 21 antibiotic prescriptions to 11 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dupixent | 39 | $138,434 | $3,550 |
| Cosentyx Sensoready (2 Pens) | 11 | $79,459 | $7,224 |
| Clobetasol Propionate | 40 | $2,741 | $69 |
| Ketoconazole | 105 | $1,673 | $16 |
| Fluorouracil | 23 | $1,620 | $70 |
See all 15 drugs
| Dupixent | 39 | $138,434 | $3,550 |
| Cosentyx Sensoready (2 Pens) | 11 | $79,459 | $7,224 |
| Clobetasol Propionate | 40 | $2,741 | $69 |
| Ketoconazole | 105 | $1,673 | $16 |
| Fluorouracil | 23 | $1,620 | $70 |
| Tacrolimus | 15 | $1,598 | $107 |
| Fluocinonide | 38 | $1,421 | $37 |
| Triamcinolone Acetonide | 77 | $667 | $9 |
| Ciclopirox | 13 | $607 | $47 |
| Clindamycin Phosphate | 20 | $516 | $26 |
| Doxycycline Hyclate | 16 | $395 | $25 |
| Minoxidil | 21 | $347 | $17 |
| Mupirocin | 30 | $182 | $6 |
| Hydrocortisone | 20 | $158 | $8 |
| Prednisone | 15 | $93 | $6 |
Year by year
| 2024 | 597 | 180 | 0% (0) | 12% | $400,105 |
| 2023 | 414 | 130 | 0% (0) | None | $167,356 |
| 2022 | 70 | 34 | 0% (0) | None | $9,308 |
| 2021 | 103 | 49 | None | None | $9,298 |
| 2020 | 102 | 41 | 0% (0) | None | $4,982 |
| 2019 | 72 | 19 | 0% (0) | 32% | $10,328 |
| 2018 | 22 | 11 | 0% (0) | None | $2,529 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Dupixent | 22 | $85,395 | $3,882 |
| Fluocinonide | 25 | $1,861 | $74 |
| Clobetasol Propionate | 26 | $1,754 | $67 |
| Ketoconazole | 66 | $1,267 | $19 |
| Triamcinolone Acetonide | 52 | $634 | $12 |
| Hydrocortisone | 36 | $436 | $12 |
| Mupirocin | 19 | $181 | $10 |
| Minoxidil | 20 | $131 | $7 |
2022: 1 drug
| Ketoconazole | 12 | $312 | $26 |
2021: 2 drugs
| Ketoconazole | 12 | $206 | $17 |
| Prednisone | 13 | $67 | $5 |
2020: 1 drug
| Ketoconazole | 14 | $355 | $25 |
2019: 1 drug
| Fluconazole | 11 | $83 | $8 |
Money from drug and device companies
$298 in 2025
| 2025 | 1 | 2 | None | $298 |
| 2023 | 1 | 1 | None | $15 |
| 2021 | 1 | 2 | None | $52 |
| 2020 | 1 | 1 | None | $125 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Galderma Laboratories L.P. | Nemluvio | $298 | 2 payments
|
See all 2 published payments
| Galderma Laboratories L.P. | Meals · 2025-08-19 | None | $170 |
| Galderma Laboratories L.P. | Meals · 2025-05-27 | Nemluvio | $129 |
See earlier years (2023, 2021, 2020)
2023: $15
| Pfizer | Cibinqo | $15 | 1 payment
|
2021: $52
| AbbVie | Humira | $52 | 2 payments
|
2020: $125
| Regeneron Healthcare Solutions | Dupixent | $125 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1538650213
- Licence
- CA A165376California A165376: Current · expires 2027-09-30
- Trained
- Perelman School of Med at the University of Pennsylvania, 2018
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2018-05-29
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 800 Spruce St, Philadelphia, PA, 19107 · 450 Broadway Ave, Redwood City, CA, 94063